CA2878370A1 — Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
Assigned to Santen Pharmaceutical Co Ltd · Expires 2014-01-16 · 12y expired
What this patent protects
A combination of drugs for the prevention or treatment of glaucoma or ocular hypertension, said combination being useful as a prevention or treatment agent for glaucoma or ocular hypertension. Ocular tension lowering effects can be mutually complemented and/or enhanced by combini…
USPTO Abstract
A combination of drugs for the prevention or treatment of glaucoma or ocular hypertension, said combination being useful as a prevention or treatment agent for glaucoma or ocular hypertension. Ocular tension lowering effects can be mutually complemented and/or enhanced by combining (6-{[4-(pyrazole-1-yl)benzyl](pyridine-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino) isopropyl acetate and other drugs for the prevention or treatment of glaucoma or ocular hypertension. The drugs can be administered either as a combined administration or as a mixture.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.